A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Related Articles

See more

Details 詳細情報について

  • CRID
    1370004238396142080
  • Data Source
    • Crossref
Back to top